Skip to content

The Safety and Effectiveness of Zhusheyong Yiqifumai (freeze-dried) in the treatment of Sepsis with Deficiency of Qi and Yin- A Randomized, Single-blind, Placebo-controlled pilot Clinical Trial

The Safety and Effectiveness of Zhusheyong Yiqifumai (freeze-dried) in the treatment of Sepsis with Deficiency of Qi and Yin- A Randomized, Single-blind, Placebo-controlled Clinical Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057075
Enrollment
Unknown
Registered
2022-02-27
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Treatment group:Standard treatment of sepsis and Zhusheyong Yiqifumai (freeze-dried)
Control group:Standard treatment of sepsis

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 89 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria of sepsis and deficiency syndrome of Qi and Yin; 2. Male or female, aged 18-90 (boundary value included); 3. Subjects and/or legal guardians voluntarily participate in the study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Known allergy to the test drug as well as to the excipients or similar drugs, self-reported susceptibility to hypersensitivity; 2. Subjects with severe intracranial disease (intracranial arterial stenosis, intracranial infection, cerebral hemorrhage, cerebral infarction, traumatic brain injury, post-cranial surgery); 3. Including but not limited to patients with severe brain injury, after cardiopulmonary resuscitation, advanced malignant tumor, and severe primary diseases of the liver, lung, kidney, and hematopoietic system, with a very poor prognosis; 4. Patients with autoimmune diseases, immunodeficiency diseases, continuous use of immunosuppressive drugs within the last 6 months, or organ transplants; 5. Major surgery or serious trauma within the last 2 weeks; 6. Female subjects who are pregnant; 7. Participation in another clinical drug trial in the 1 month prior to the trial; 8. Poor compliance or other clinical, social, or family factors that, in the opinion of the investigator, make inclusion in the study inappropriate.

Design outcomes

Primary

MeasureTime frame
Death rate;Length of ICU stay;Incidence of re-entry into ICU;Absolute lymphocyte values;TB lymphocyte subsets;Cytokine detection;

Secondary

MeasureTime frame
Duration of vasoactive drugs;Duration of mechanical ventilation;Duration of continuous renal replacement therapy;SOFA score;Quantities of fluid resuscitation;Duration of fluid resuscitation;Anxiety depression Scale;BARTHEL score;TCM syndrome score;Mean arterial pressure;Heart rate;Blood lactate;Lactate clearance rate;Detection of myocardial lesion, NT-proBNP;Blood gas analysis Rusults;Coagulation examination,TAT/PIC/TM/tPAIC;APACHEII scale;Immunoprotein assay,complement determination;24-hour urine volume;Blood routine examination, urine routine;C-reactive protein, procalcitonin;Respiratory rate;Liver and kidney function;Input and output amount;Oxygenation Index;

Countries

China

Contacts

Public ContactZhixu Yang

Xiyuan Hospital, China Academy of Chinese Medical Sciences

yangzhixu@sohu.com+86 13366130101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026